Search results below include Worst Pills, Best Pills Newsletter Articles where your
selected drug is a primary subject of discussion.
Neuroleptic malignant syndrome is a life-threatening neurological disorder most often caused by neuroleptic (antipsychotic) medications, which are used to treat schizophrenia and certain other psychiatric disorders, among other things. The syndrome also can be caused by certain other drugs used to treat nausea and depression, as well as by the sudden discontinuation of a dopamine agonist (drugs that are used most commonly to treat Parkinson’s disease).
Although impaired driving usu¬ally is caused by alcohol or marijuana, many commonly used prescription and over-the-counter medications also can impair one’s ability to drive safely. Learn about several classes of medications that can cause this serious problem to protect yourself, your passengers and others who share the road with you.
Patients taking the commonly prescribed antifungal drug fluconazole (DIFLUCAN) should be aware that it has clinically important interactions with many other prescription medications. Some of these interactions can lead to an increased risk of fatal heart rhythm abnormalities.
Next to Parkinson’s disease, drug-induced parkinsonism is the second most common cause of parkinsonism, accounting for about 8-12% of all parkinsonism cases. Find out which commonly used drugs can cause this condition.
Read about the more than two dozen medications that can have clinically important interactions with aripiprazole, one of the widely used newer atypical antipsychotic drugs that is approved by the FDA for treatment of several disorders including schizophrenia, bipolar disorder and depression.
Some powerful antipsychotic drugs originally developed to treat schizophrenia now have been approved to treat depression. Learn about the serious side effects of these drugs that make it advisable to explore other, safer options for managing depression.
The federal government recently issued guidelines discouraging the use of antipsychotic medications to treat dementia in nursing home patients, promoting nonpharmacologic approaches to such treatment. Antipsychotic use among elderly patients is associated with increased chances of death, as well as other serious side effects.
The article lists 27 drugs that can cause akathisia, a condition characterized by muscular quivering and the inability to sit still. Other signs of the condition include fidgety movements, leg swinging while sitting, rocking from foot to foot or pacing and motor restlessness.
The article describes the symptoms of the life-threatening neurological disorder neuroleptic malignant syndrome (NMS) and lists 40 different prescription drugs that have been found to cause it.
A study discovered that more than 1 out of every 10 people who went to a Parkinson’s disease center was found to have drug-induced Parkinsonism. These people were misdiagnosed as having the more common illness, Parkinson’s disease, which is irreversible and has unknown causes.
The article lists 53 drugs that can interact with the psychiatric drug ABILIFY to either increase the amount in the body, which can lead to toxicity, or decrease the amount rendering the drug less effective.
The article discusses numerous recent examples of the harm that has been caused by off-label prescribing, including the heart drugs amiodarone (Cordarone), many antipsychotic drugs, topiramate (Topamax)and several antidepressants.
Elderly patients with dementia-related psychosis treated with atypical antipsychotic drugs are at an increased risk of death compared to placebo...The percentage of patients using antipsychotic drugs in the six nursing homes receiving training and support was significantly lower (23 percent) than that in the nursing homes whose patients received usual care (42.1 percent).
Clearly, the concern here is that the use of atypical and typical antipsychotic drugs to control the behavior of elderly nursing home residents who are not psychotic could be considered an unlawful chemical restraint.
FDA relabels these drugs due to an increased risk of death among patients taking the drugs off-label for dementia.
You should follow the Health Research Group’s Seven Year Rule with aripiprazole. There is no evidence to suggest that aripiprazole is a “breakthrough” drug.